Dual bronchodilation for the treatment of chronic obstructive pulmonary disease: a review of the latest clinical data

2014 ◽  
Vol 4 (6) ◽  
pp. 511-533 ◽  
Author(s):  
Donald Banerji ◽  
Robert Fogel ◽  
Kai-Michael Beeh
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Clinical Data ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Dual Bronchodilation

scholarly journals The Nursing Measures of Chronic Obstructive Pulmonary Disease with Respiratory Failure Treated by Noninvasive Ventilator

2012 ◽  
Vol 1 ◽  
pp. 9
Author(s):  
Rong Chen
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Respiratory Failure ◽  
Pulmonary Disease ◽  
Clinical Data ◽  
Ph Value ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

<p><strong>Objective: </strong>To analyze the nursing measures and curative effects of chronic obstructive pulmonary disease with respiratory failure treated by noninvasive ventilator;<strong> Methods:</strong> Retrospectively analyze the clinical data in 35 cases of chronic obstructive pulmonary disease with respiratory failure treated by noninvasive ventilator between June 2011 and June 2012 in the hospital; <strong>Results:</strong> All the patients’ conditions were improved after the treatment and nursing, and the differences of pH value, PaO<sub>2</sub>, PaCO<sub>2 </sub>were significant (<em>p </em>&lt; 0.05); <strong>Conclusion:</strong> Effective nursing measures can enhance the curative effects when the noninvasive ventilator is applied to the treatment of chronic obstructive pulmonary disease with respiratory failure.<strong></strong></p>

scholarly journals The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease

2020 ◽  
Vol 14 ◽  
pp. 175346662092680
Author(s):  
Kyriakos Souliotis ◽  
Luís Silva Miguel ◽  
Georgios Hillas ◽  
Margarida Borges ◽  
Giannis Papageorgiou ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Budget Impact ◽  
Healthcare Resource ◽  
Cost Savings ◽  
Base Case ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Dual Bronchodilation ◽  
Long Acting

Purpose: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018 recommendations support maintenance treatment with long-acting bronchodilators in most symptomatic patients with chronic obstructive pulmonary disease (COPD). While restricting the overuse of inhaled corticosteroids (ICS) may influence healthcare utilization required to treat inadvertent respiratory (exacerbations and pneumonia) and diabetes-related events, it may also change the total medication cost. This analysis was performed to estimate the 5-year budget impact of switching from ICS-containing treatment combinations to dual bronchodilation, in line with the recommendations. Methods: The model quantified the budget impact of treatment and healthcare resource utilization when COPD patients were anticipated to switch from ICS-containing treatments to dual bronchodilation. Three switch scenarios were calculated with increasing proportions of patients on dual long-acting bronchodilators, to the detriment of ICS-containing double and triple combinations. Clinical and cost input data were based on results from clinical trials and Greek and Portuguese healthcare cost databases. Results: Healthcare resource use to manage exacerbations, pneumonia and diabetes-related events were projected to increase between 2019 and 2023 in parallel with the growing COPD patient population and associated costs were estimated at 52–57% of the total disease cost in the Greek and Portuguese base case scenarios. Total cost savings between 21 and 112 million EUR were projected when the proportion of patients on double and triple ICS-containing treatments was gradually reduced to 50% in scenario A, 20% in scenario B and 7% in scenario C. Sensitivity analyses showed that none of the model assumptions had a major impact on the projected savings. Conclusion: The alignment of COPD treatment with current recommendations may bring clinical benefits to patients, without substantial cost increases and even cost savings for payers. The reviews of this paper are available via the supplemental material section.

Sign in / Sign up

Export Citation Format

Share Document